Dissecting factors influencing response to CAR T cell therapy in B lymphoid hematologic malignancies: from basic to practice.

Leukemia & Lymphoma
Kitsada Wudhikarn, Jae H Park

Abstract

Over the past recent years, CD19-targeted chimeric antigen receptor T (CAR T) cell has transformed the treatment of relapsed/refractory (R/R) B lymphoid hematologic malignancy. CAR T cell therapy elicits an excellent anti-tumor effect and extends long-term disease-free remission in these difficult-to-treat patients. Notwithstanding, despite the impressive anti-tumor efficacy, some patients fail to attain clinical response or relapse after extended follow-up. The success of CAR T cell therapy involves complex interplays between host, tumor, and CAR T cell-associated arrays. Researchers have extensively explored potential predictive biomarkers for response to CAR T cell therapy. Ability to identify clinical and biological factors associated with improved response will help determine appropriate patients for CAR T cell treatment and enhance the clinical outcome of this novel therapeutic approach.

References

Aug 13, 2011·The New England Journal of Medicine·David L PorterCarl H June
Sep 20, 2011·Nature Medicine·Luca GattinoniNicholas P Restifo
Apr 12, 2012·Blood·Nicola GökbugetUNKNOWN German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Aug 27, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Dec 19, 2014·The Journal of Immunology : Official Journal of the American Association of Immunologists·Keisuke WatanabeMakoto Murata
Jan 8, 2016·Science Translational Medicine·Nathan SinghDavid M Barrett
Apr 26, 2016·The Journal of Clinical Investigation·Cameron J TurtleDavid G Maloney
May 22, 2016·Blood·Jennifer N Brudno, James N Kochenderfer
Mar 16, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James N KochenderferSteven A Rosenberg
Aug 15, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·James N KochenderferSteven A Rosenberg
Dec 12, 2017·The New England Journal of Medicine·Eric TranWalter J Urba
Dec 12, 2017·The New England Journal of Medicine·Sattva S NeelapuWilliam Y Go
Feb 1, 2018·The New England Journal of Medicine·Shannon L MaudeStephan A Grupp
Feb 1, 2018·The New England Journal of Medicine·Jae H ParkMichel Sadelain
Mar 20, 2018·Molecular Therapy. Methods & Clinical Development·Michael C Milone, Vijay G Bhoj
Jun 19, 2018·Molecular Therapy : the Journal of the American Society of Gene Therapy·Mark B GeyerJae H Park
Aug 12, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gunilla EnbladAngelica Loskog
Aug 25, 2018·Blood·Marco L Davila
Sep 8, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen Thudium MuellerShannon L Maude
Dec 7, 2018·The New England Journal of Medicine·Stephen J SchusterUNKNOWN JULIET Investigators
Mar 13, 2019·The Journal of Clinical Investigation·Olivia C FinneyMichael C Jensen
Apr 19, 2019·Journal for Immunotherapy of Cancer·Jessica FesslerThomas F Gajewski
May 3, 2019·The New England Journal of Medicine·Noopur RajeJames N Kochenderfer
May 18, 2019·American Society of Clinical Oncology Educational Book·Bianca SantomassoElizabeth J Shpall

❮ Previous
Next ❯

Citations

Feb 26, 2021·Current Hematologic Malignancy Reports·Taha Al-Juhaishi, Sairah Ahmed
May 29, 2021·EBioMedicine·Jie ZhangHongyan Guo
Jul 3, 2021·International Journal of Molecular Sciences·Álvaro Martínez-RubioMaría Rosa

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.